March 28, 2017 / 2:07 PM / 5 months ago

BRIEF-Oncology Venture in-licenses 2-BBB's Phase 2 product 2B3-101 for 2X Oncology's pipeline

March 28 (Reuters) - ONCOLOGY VENTURE SWEDEN AB:

* ONCOLOGY VENTURE SWEDEN AB (OV:ST) AND 2-BBB MEDICINES BV ANNOUNCE TODAY TO HAVE ENTERED INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT ON 2-BBB’S PHASE 2 LEAD PRODUCT 2B3-101 – NOW CALLED 2X-111

Source text: bit.ly/2nHX3HU

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below